Shares of Oncothyreon (ONTY) fall 32.4% in premarket trading after Merck KgaA (MKGAF.PK) announces that studies on the experimental lung-cancer drug Stimuvax won't be completed until next year. Stimuvax is being developed by Merck KGaA under a license agreement with Oncothyreon.
Shares of Oncothyreon (ONTY) fall 32.4% in premarket trading after Merck KgaA (MKGAF.PK)...
From other sites
at CNBC.com (Feb 24, 2012)
at CNBC.com (Jun 24, 2011)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs